Shots: CRISPR to receive $900M up front with an additional $200M milestone upon the regulatory approval of CTX001. Vertex will responsible for the global development, manufacturing, and commercialization of CTX001 […]readmore
Tags : Collaboration
Shots: Boehringer Ingelheim and MD Anderson expand their 2019 joint VRDC to explore new molecules from Boehringer Ingelheim’s KRAS and TRAILR2 portfolios for lung cancer, particularly NSCLC The joint research […]readmore
Shots: Merck KGaA selects PRA’s remote patient monitoring platform to work in combination with its HGH treatment system PRA’s remote patient monitoring platform will support Merck’s KGH system including its […]readmore
In an interview with PharmaShots, Marie Schiller Vice President of Product Development for Connected Care and Insulins at Lilly shared her views on its collaboration with Welldoc to integrate Welldoc’s insulin management […]readmore
Shots: F-star to receive option exercise payment and will be eligible to get milestones and royalties on net sales of therapies resulting from the collaboration Merck KGaA exercises its third […]readmore
In an interview with PharmaShots, John Valliant, CEO at Fusion Pharma shared his views on the company’s agreement with AstraZeneca, signed in Nov 2020. He also shared in-depth information about […]readmore
Shots: The companies plan to initiate a P-IIb study assessing NovoNordisk’s semaglutide and FD combination of Gilead’s cilofexor + firsocostat vs PBO in ~440 patients with compensated cirrhosis (F4) due […]readmore
In an interview with PharmaShot, Dr. Sophia Randolph, Chief Medical Officer of ALX Oncology shared her views on the ALX Oncology’s collaboration with Zymework for evaluating the combination with ALX148 […]readmore
Shots: X-Chem to receive an up front and is eligible to receive research, development and regulatory milestone along with royalties on sales of therapies resulting from the collaboration Genentech will […]readmore
Shots: ImmunoGen to receive $40M up front, ~$265M as development, regulatory & commercial milestones and is eligible to receive royalties on sales of mirvetuximab in Greater China and will retain […]readmore